More recently, we’ve actually published long-term data from EMBARK showing that ADT plus enzalutamide significantly and really dramatically improved overall survival, whereas overall survival for monotherapy was numerically better than ADT but this did not reach statistical significance [ 6 ]; and importantly we preserved quality of life, with no new safety signals [ 1 , 2 ].
← all excerpts
Enzalutamide in biochemically recurrent prostate cancer: key findings from subsequent analyses of EMBARK and their implications in clinical practice.
1
—
—